GitLab To Announce First Quarter Fiscal 2026 Financial Results
Get Alerts GTLB Hot Sheet
Join SI Premium – FREE
SAN FRANCISCO--(BUSINESS WIRE)-- All Remote - GitLab Inc., (NASDAQ: GTLB), the most comprehensive, intelligent DevSecOps platform, today announced that it will report its financial results for the first quarter of fiscal year 2026, which ended April 30, 2025, after U.S. markets close on Tuesday, June 10, 2025. Management will host a conference call and webcast on the same day to discuss the company’s financial results at 4:30 p.m. ET / 1:30 p.m. PT.
GitLab First Quarter Fiscal 2026 Financial Results Conference Call and Webcast
When: Tuesday, June 10, 2025
Time: 4:30 p.m. ET / 1:30 p.m. PT
Replay: A webcast replay of the conference call will be available on the investor relations website for one year.
GitLab uses its Investor Relations website ir.gitlab.com and its X feed (@gitlab), among other channels, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
About GitLab Inc.
GitLab is the most comprehensive, intelligent DevSecOps platform for software innovation. GitLab enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. More than 50 million registered users and more than 50% of the Fortune 100 trust GitLab to ship better, more secure software faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520661247/en/
Media Contact:
Lisa Boughner
[email protected]
Investor Contact:
Kelsey Turcotte
[email protected]
Source: GitLab Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
- Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share